博客

免疫球蛋白

IVIG用于实体器官移植

Doctor showing plastic model of human kidney and addresses how IVIG can help with solid organ transplantation.

Solid organ transplantation is a surgical procedure that replaces a person’s failing organ with a healthy one from a donor. It is a vital procedure that can benefit people who are suffering from severe organ failure. 

询问 IVIG 家庭输液

(877) 778-0318

However, there are several challenges of solid organ transplantation. One challenge that patients often face is organ rejection. This happens when the body’s immune system misidentifies the new organ as a foreign, harmful object and attacks it. To prevent this, doctors use immunosuppressant drugs that weaken their immune system, but this will also increase the risk of infection [1].

静脉注射免疫球蛋白(IVIG) can help prevent transplant rejection. In this article, we will discuss IVIG and how it can enhance your chances of successful organ transplantation.

IVIG 是什么?

Intravenous Immunoglobulin (IVIG) is a treatment made from the plasma of thousands of donors, containing many different antibodies. IVIG can help you fight infections if you have a weakened immune system. It is used in various immune system disorders and inflammatory diseases like 川崎病, lupus, and guillain-barre syndrome

There are many benefits of IVIG for solid organ transplantation. IVIG can calm an overactive immune system, thus reducing the chance of organ rejection. Before and after surgery, you must take immunosuppressant drugs, which weakens your immune system. This makes you more prone to infections, and IVIG can help you fight these infections. In short, IVIG can make your transplant more successful and keep you healthier. 

What Are the Benefits of IVIG for Solid Organ Transplantation?

Intravenous Immunoglobulin (IVIG) is a good supporting treatment option for solid organ transplantation. It can play a vital role in both the preparation of an organ transplant and management of the potential complications that come after the transplant. Below, we will discuss how IVIG can help you in different stages of organ transplantation.

Role of IVIG Before Organ Transplantation

3D illustration of antibodies on a blue cell background

Before solid organ transplantation, doctors primarily use intravenous immunoglobulin (IVIG) for desensitization. Desensitization is a medical process that reduces antibodies in a patient’s blood that could harm a transplanted organ. You need to go through this process before organ transplantation if you have high levels of alloantibodies, which are antibodies that target transplanted organs. The higher the levels of alloantibodies present in your blood, the longer you have to wait before conducting surgery. 

In the past two decades, doctors have used IVIG as a tool for the desensitization process in kidney transplantation. It can reduce the alloantibody levels in your body, which can increase your chance of a successful organ transplant [2][5]. For the desensitization process, doctors use IVIG alone or in combination with other treatments like steroids, plasma exchange, and immunosuppressive drugs like 利妥昔单抗 [3][5]. 

Most of the documented success of IVIG in the desensitization process has been in kidney transplants. According to one study, there is a lack of evidence to support the use of IVIG for the desensitization process in heart, lung, and liver transplants [5]. However, a recent Canadian study suggested that the combined use of IVIG, plasma exchange, anti-thymocyte globulin, and mycophenolic acid can benefit patients who have high levels of alloantibodies during lung transplants [4].

获得 IVIG 共同支付援助

了解更多

Role of IVIG After Organ Transplantation

After the organ transplantation, the primary concern is to prevent organ rejection. You may experience organ rejection within the first few months or after a long time. The rejection may be caused by cells or antibodies. If antibodies cause the rejection, then it is called antibody-mediated rejection (AMR). If doctors suspect AMR, they will implement a treatment regimen to suppress your immune system and save the transplanted organ.

Various studies over the past decades have shown that using IVIG in combination with drugs like rituximab can lower your risk of organ rejection in kidney transplants [7][8]. It is also beneficial in treating AMR in other transplants like lung, heart, and liver [9].

There is another notable complication that comes after your organ transplant. Many patients experience low levels of 免疫球蛋白 due to the use of immunosuppressants [10]. This can make you more prone to infections. In this case, IVIG therapy can help you replenish immunoglobulin levels and protect you against infections. According to one study, the usage of IVIG can reduce your risk of getting infections after an organ transplant [11].

底线

For over a decade, IVIG has been very useful in solid organ transplantation. It can ensure the long-term survival of a transplant recipient by lowering the alloantibody levels, preventing AMR (antibody-mediated rejection), and managing infections. However, we still need more research to understand the full potential of IVIG for solid organ transplantation.

参考:

  1. Black, C. K., Termanini, K. M., Aguirre, O., Hawksworth, J. S., & Sosin, M. (2018). Solid organ transplantation in the 21st century. Annals of Translational Medicine, 6(20), 409. https://doi.org/10.21037/atm.2018.09.68
  2. Sethi, S., Choi, J., Toyoda, M., Vo, A., Peng, A., & Jordan, S. C. (2017). Desensitization: overcoming the immunologic barriers to transplantation. Journal of Immunology Research, 2017, 1–11. https://doi.org/10.1155/2017/6804678
  3. Guo, Z., Zhao, D., Sa, R., Wang, L., Li, S., Zhao, G., Zhu, L., & Chen, G. (2023). A modified perioperative regimen for deceased donor kidney transplantation in presensitized recipients without prior desensitization therapy. Frontiers in Immunology, 14. https://doi.org/10.3389/fimmu.2023.1223567
  4. Tinckam, K., Keshavjee, S., Chaparro, C., Barth, D., Azad, S., Binnie, M., Chow, C., De Perrot, M., Pierre, A., Waddell, T., Yasufuku, K., Cypel, M., & Singer, L. (2015). Survival in sensitized lung transplant recipients with perioperative desensitization. American Journal of Transplantation, 15(2), 417–426. https://doi.org/10.1111/ajt.13076
  5. Shehata, N., Palda, V. A., Meyer, R. M., Blydt-Hansen, T. D., Campbell, P., Cardella, C., Martin, S., Nickerson, P., Peltekian, K., Ross, H., Waddell, T. K., West, L., Anderson, D., Freedman, J., & Hume, H. (2009). The use of Immunoglobulin therapy for Patients undergoing solid Organ Transplantation: An Evidence-Based Practice Guideline. Transfusion Medicine Reviews, 24, S7–S27. https://doi.org/10.1016/j.tmrv.2009.09.010
  6. Jordan, S. C., Tyan, D., Stablein, D., McIntosh, M., Rose, S., Vo, A., Toyoda, M., Davis, C., Shapiro, R., Adey, D., Milliner, D., Graff, R., Steiner, R., Ciancio, G., Sahney, S., & Light, J. (2004). Evaluation of Intravenous Immunoglobulin as an Agent to Lower Allosensitization and Improve Transplantation in Highly Sensitized Adult Patients with End-Stage Renal Disease. Journal of the American Society of Nephrology, 15(12), 3256–3262. https://doi.org/10.1097/01.asn.0000145878.92906.9f
  7. Lachmann, N., Duerr, M., Schönemann, C., Pruß, A., Budde, K., & Waiser, J. (2017). Treatment of Antibody-Mediated Renal Allograft Rejection: Improving step by step. Journal of Immunology Research, 2017, 1–9. https://doi.org/10.1155/2017/6872046
  8. Takemoto, S. K., Zeevi, A., Feng, S., Colvin, R. B., Jordan, S., Kobashigawa, J., Kupiec-Weglinski, J., Matas, A., Montgomery, R. A., Nickerson, P., Platt, J. L., Rabb, H., Thistlethwaite, R., Tyan, D., & Delmonico, F. L. (2004). National Conference to Assess Antibody-Mediated Rejection in Solid Organ Transplantation. American Journal of Transplantation, 4(7), 1033–1041. https://doi.org/10.1111/j.1600-6143.2004.00500.x
  9. Ig Governance – Criteria for the clinical use of immunoglobulin in Australia. (n.d.). https://www.criteria.blood.gov.au/MedicalCondition/View/2484
  10. Works CitedPerez, Elena E., et al. “Update on the Use of Immunoglobulin in Human Disease: A Review of Evidence.” Journal of Allergy and Clinical Immunology, vol. 139, no. 3, Mar. 2017, pp. S1–S46, www.aaaai.org/Aaaai/media/MediaLibrary/PDF%20Documents/Practice%20and%20Parameters/IVIG-March-2017.pdf, https://doi.org/10.1016/j.jaci.2016.09.023.
  11. Carbone, J., Fernandez-Yañez, J., Montanchez, J., Zatarain, E., Navarro, J., Rodriguez-Ferrero, M., Anaya, F., Salcedo, M., Fernandez, A., Muñoz, P., Valerio, M., & Sarmiento, E. (2018). Intravenous Immunoglobulin Replacement Therapy in Solid Organ Transplantation with Severe Infections and Secondary Antibody Deficiency. Transplantation, 102(Supplement 7), S84. https://doi.org/10.1097/01.tp.0000542670.27264.65
此信息不能替代医疗建议或治疗。在开始任何新的治疗之前,请咨询您的医生或医疗保健提供者,了解您的医疗状况。AmeriPharma® Specialty Care 对所提供的信息或由此做出的任何诊断或治疗不承担任何责任,也不对其内容的可靠性负责。AmeriPharma® Specialty Care 并非运营此处列出的所有网站/组织,也不对其内容的可用性或可靠性负责。这些列表并不暗示或构成 AmeriPharma® Specialty Care 的认可、赞助或推荐。本网页可能包含对品牌处方药的引用,这些处方药是与 AmeriPharma® Specialty Care 无关的制药商的商标或注册商标。
Portrait of Christine L., a healthcare professional, smiling confidently.
医学审核人 Christine Leduc 博士,药学博士

Christine Leduc 博士,药学博士,在加州尔湾市出生长大。她就读于中西部大学,并以优异成绩毕业。她工作中最有成就感的部分是建议改变生活方式,教育患者了解药物的药理作用,以及指导未来的药剂师。她的专业领域是客户服务和专科药物知识。她曾在服务行业工作,积累了理解患者需求所需的客户服务技能。Leduc 博士目前正在指导马歇尔·B·凯彻姆大学、堪萨斯大学和中西部大学的学生。闲暇时,她喜欢旅行、烘焙和园艺。 参见作者简介

联系我们

使用下方符合 HIPAA 标准的表格申请续药。如果您对药物或用药方法有任何疑问,请访问“联系我们”页面或致电 (877) 778-0318.

HIPAA Compliant

提交即表示您同意 AmeriPharma 的 使用条款, 隐私政策, 和 隐私惯例通知

zh_CNChinese